Genome & Company (KOSDAQ:314130)
South Korea
· Delayed Price · Currency is KRW 2,205.00
-65.00 (-2.86%)
At close: Mar 31, 2025, 3:30 PM KST
Genome & Company Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Operating Revenue | 27,745 | 14,296 | 14,085 | 451.25 | 150.58 | Upgrade
|
| Other Revenue | -0 | - | -0 | - | - | Upgrade
|
| Revenue | 27,745 | 14,296 | 14,085 | 451.25 | 150.58 | Upgrade
|
| Revenue Growth (YoY) | 94.07% | 1.50% | 3021.27% | 199.67% | 228.54% | Upgrade
|
| Cost of Revenue | 12,075 | 10,232 | 8,487 | 77.01 | - | Upgrade
|
| Gross Profit | 15,670 | 4,064 | 5,598 | 374.24 | 150.58 | Upgrade
|
| Selling, General & Admin | 22,025 | 28,677 | 19,664 | 14,123 | 12,915 | Upgrade
|
| Research & Development | 13,379 | 25,666 | 36,793 | 21,263 | 13,669 | Upgrade
|
| Operating Expenses | 39,869 | 59,156 | 63,110 | 36,461 | 26,779 | Upgrade
|
| Operating Income | -24,199 | -55,092 | -57,512 | -36,087 | -26,629 | Upgrade
|
| Interest Expense | -3,541 | -1,738 | -175 | -54.92 | -1,236 | Upgrade
|
| Interest & Investment Income | 3,778 | 4,121 | 850.8 | 458.17 | 112.52 | Upgrade
|
| Currency Exchange Gain (Loss) | -52.4 | -40.56 | -29.46 | -468.02 | 76.85 | Upgrade
|
| Other Non Operating Income (Expenses) | 4,206 | 3,252 | -1,112 | 161.16 | -3,418 | Upgrade
|
| EBT Excluding Unusual Items | -19,808 | -49,499 | -57,979 | -35,991 | -31,093 | Upgrade
|
| Gain (Loss) on Sale of Investments | 40.28 | 46.44 | -54.79 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -79.51 | -77.11 | 0.69 | -12.93 | -92.58 | Upgrade
|
| Asset Writedown | -8,367 | -2,325 | - | - | - | Upgrade
|
| Pretax Income | -28,215 | -51,855 | -58,033 | -36,004 | -31,186 | Upgrade
|
| Income Tax Expense | -1,365 | -1,202 | -1,083 | - | - | Upgrade
|
| Earnings From Continuing Operations | -26,850 | -50,653 | -56,950 | -36,004 | -31,186 | Upgrade
|
| Minority Interest in Earnings | 6,737 | 3,187 | 5,112 | 1,887 | 453.56 | Upgrade
|
| Net Income | -20,112 | -47,466 | -51,838 | -34,117 | -30,732 | Upgrade
|
| Net Income to Common | -20,112 | -47,466 | -51,838 | -34,117 | -30,732 | Upgrade
|
| Shares Outstanding (Basic) | 30 | 28 | 28 | 27 | 19 | Upgrade
|
| Shares Outstanding (Diluted) | 30 | 28 | 28 | 27 | 19 | Upgrade
|
| Shares Change (YoY) | 7.86% | 0.37% | 4.71% | 39.60% | 20.11% | Upgrade
|
| EPS (Basic) | -660.00 | -1680.00 | -1841.50 | -1269.10 | -1595.95 | Upgrade
|
| EPS (Diluted) | -660.00 | -1680.00 | -1841.50 | -1269.10 | -1596.00 | Upgrade
|
| Free Cash Flow | -20,301 | -51,077 | -50,399 | -29,034 | -19,662 | Upgrade
|
| Free Cash Flow Per Share | -666.18 | -1807.83 | -1790.39 | -1080.03 | -1021.03 | Upgrade
|
| Gross Margin | 56.48% | 28.43% | 39.74% | 82.94% | 100.00% | Upgrade
|
| Operating Margin | -87.22% | -385.37% | -408.34% | -7997.20% | -17683.84% | Upgrade
|
| Profit Margin | -72.49% | -332.02% | -368.05% | -7560.62% | -20409.23% | Upgrade
|
| Free Cash Flow Margin | -73.17% | -357.28% | -357.83% | -6434.20% | -13057.09% | Upgrade
|
| EBITDA | -16,752 | -46,820 | -48,051 | -33,496 | -25,164 | Upgrade
|
| EBITDA Margin | -60.38% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 7,447 | 8,272 | 9,462 | 2,591 | 1,464 | Upgrade
|
| EBIT | -24,199 | -55,092 | -57,512 | -36,087 | -26,629 | Upgrade
|
| EBIT Margin | -87.22% | - | - | - | - | Upgrade
|
| Advertising Expenses | 3,803 | 2,033 | 1,505 | 987.32 | 207.99 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.